Conclusion The relationships between mortality an

Quote:

---

Conclusion
The relationships between mortality and both time to plasma transfusion, and antibody levels provide a signature that is consistent with efficacy for the use of convalescent plasma in the treatment of hospitalized COVID-19 patients.

---

Conclusion: The successful P2 trial of Leronlimab with Per Protocol Population in a double-blinded clinical trial yielded statistically significant p-values for NEWS2 scores of p<0.03 and p<0.02 at 3 and 14 days respectively that is consistent with efficacy for the use of Mild-to Moderate COVID patients.